Patents Assigned to MEDIGENEBIO CORPORATION
-
Publication number: 20210213109Abstract: A pharmaceutical composition including an iduronate-2-sulfatase beta (IDS-?) may be administered into the cerebral lateral ventricle once every four weeks to treat Hunter syndrome in a subject. Compared to a single administration of the same dose of an active substance, due to repeated administrations over a long period of time, the administration exhibits superior effects in treating Hunter syndrome, and further has the following effects which cannot be anticipated from the result of a single administration: treating or restoring a damaged brain structure; and substantially treating or improving brain functions, particularly, improving memory and learning.Type: ApplicationFiled: May 30, 2019Publication date: July 15, 2021Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATIONInventor: Jae Yeon YEO
-
Patent number: 11052135Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.Type: GrantFiled: December 21, 2016Date of Patent: July 6, 2021Assignees: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Torayuki Okuyama, Thong-Gyu Jin, Han-Yeul Byun, Jin-Wook Seo, Byoung-Ju Lee, Yong-Chul Kim, In-Young Jang, Kyuhyun Lee
-
Publication number: 20200268857Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.Type: ApplicationFiled: December 21, 2016Publication date: August 27, 2020Applicants: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Torayuki OKUYAMA, Thong-Gyu JIN, Han-Yeul BYUN, Jin-Wook SEO, Byoung-Ju LEE, Yong-Chul KIM, In-Young JANG, Kyuhyun LEE
-
Publication number: 20200093899Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.Type: ApplicationFiled: November 27, 2019Publication date: March 26, 2020Applicants: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Jin-Kyung LEE, Han-Yeul BYUN, Myung-Eun JUNG, Kyu-Hyun LEE
-
Patent number: 10561713Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.Type: GrantFiled: July 4, 2016Date of Patent: February 18, 2020Assignees: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Jin-Kyung Lee, Han-Yeul Byun, Myung-Eun Jung, Kyu-Hyun Lee
-
Patent number: 10174299Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.Type: GrantFiled: November 14, 2017Date of Patent: January 8, 2019Assignees: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
-
Publication number: 20180303914Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.Type: ApplicationFiled: July 4, 2016Publication date: October 25, 2018Applicants: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Jin-Kyung LEE, Han-Yeul BYUN, Myung-Eun JUNG, Kyu-Hyun LEE
-
Patent number: 9896672Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: GrantFiled: June 16, 2016Date of Patent: February 20, 2018Assignees: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
-
Patent number: 9795653Abstract: A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided.Type: GrantFiled: February 14, 2014Date of Patent: October 24, 2017Assignee: MediGeneBio CorporationInventors: Sy Lee, Sung-Ick Park
-
Publication number: 20160326504Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: ApplicationFiled: June 16, 2016Publication date: November 10, 2016Applicants: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Thong-Gyu JIN, Yo Kyung CHUNG, Sang Hoon PAIK, Yoo Chang PARK, Jinwook SEO, Yong Woon CHOI, Jong Mun SON, Yong-Chul KIM
-
Publication number: 20160145589Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: ApplicationFiled: December 21, 2015Publication date: May 26, 2016Applicants: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
-
Patent number: 9249397Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: GrantFiled: July 27, 2015Date of Patent: February 2, 2016Assignees: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
-
Patent number: 9206402Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: GrantFiled: June 15, 2012Date of Patent: December 8, 2015Assignees: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
-
Publication number: 20150320843Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: ApplicationFiled: July 27, 2015Publication date: November 12, 2015Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATIONInventors: Thong-Gyu JIN, Yo Kyung CHUNG, Sang Hoon PAIK, Yoo Chang PARK, Jinwook SEO, Yong Woon CHOI, Jong Mun SON, Yong-Chul KIM
-
Publication number: 20140351964Abstract: The present invention relates to a transgenic mouse model for developing enzyme replacement therapy for iduronate-2-sulfatase deficiency syndrome, for example, Hunter syndrome. More specifically, the present invention relates to a transgenic mouse to be used for developing enzyme replacement therapy for iduronate-2-sulfatase, wherein the immune response against injected enzyme, such as, recombinant iduronate-2-sulfatase has been minimized in transgenic mouse model in the course of treating in vivo iduronate-2-sulfatase replacement.Type: ApplicationFiled: June 3, 2014Publication date: November 27, 2014Applicant: MEDIGENEBIO CORPORATIONInventor: Thong-Gyu Jin
-
Publication number: 20140242059Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: ApplicationFiled: June 15, 2012Publication date: August 28, 2014Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATIONInventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
-
Publication number: 20140162953Abstract: A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided.Type: ApplicationFiled: February 14, 2014Publication date: June 12, 2014Applicant: MEDIGENEBIO CORPORATIONInventors: Sy LEE, Sung-lck PARK